click
Contact

Tag: LXH-2103

Novel Analgesic Breakthrough: Xinhua Pharmaceutical’s Class 1 Drug LXH-2103 Secures Clinical Approval with Medicilon’s Preclinical Support

Preclinical CRO

Shandong Xinhua Pharmaceutical Co., Ltd., the core subsidiary of Shandong Hualu Holdings Co., Ltd., has obtained official clinical trial approval from the National Medical Products Administration (NMPA) for LXH-2103 Injection, its self-developed Class 1 innovative drug. The candidate is approved for clinical research in the treatment of moderate to severe postoperative pain, marking a key […]

Contact

Search Medicilon

Preclinical CRO

Breaking New Ground in Alzheimer’s Disease! Medicilon Supports Hengrui Pharma’s SHR-3201 Injection to Secure Clinical Trial Approval

Read more
Preclinical CRO

Breaking the “King of Cancer”: First-in-Class ADC MC001. Medicilon Supports Partner Medicovestor to Secure FDA IND Clearance

Read more
Preclinical CRO

Medicilon’s Dr. Chunlin Chen Engages FDA Experts at SAPA-DC Annual Conference to Discuss Global IND Development and NAMs Technologies for Innovative Medicines

Read more

Contact Medicilon

Name(Required)
Address(Required)